Last reviewed · How we verify
Anti-CS17 Bovin IgG
Anti-CS17 Bovin IgG is a Biologic drug developed by Johns Hopkins Bloomberg School of Public Health. It is currently in Phase 2 development. Also known as: Experimental.
At a glance
| Generic name | Anti-CS17 Bovin IgG |
|---|---|
| Also known as | Experimental |
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-CS17 Bovin IgG CI brief — competitive landscape report
- Anti-CS17 Bovin IgG updates RSS · CI watch RSS
- Johns Hopkins Bloomberg School of Public Health portfolio CI
Frequently asked questions about Anti-CS17 Bovin IgG
What is Anti-CS17 Bovin IgG?
Anti-CS17 Bovin IgG is a Biologic drug developed by Johns Hopkins Bloomberg School of Public Health.
Who makes Anti-CS17 Bovin IgG?
Anti-CS17 Bovin IgG is developed by Johns Hopkins Bloomberg School of Public Health (see full Johns Hopkins Bloomberg School of Public Health pipeline at /company/johns-hopkins-bloomberg-school-of-public-health).
Is Anti-CS17 Bovin IgG also known as anything else?
Anti-CS17 Bovin IgG is also known as Experimental.
What development phase is Anti-CS17 Bovin IgG in?
Anti-CS17 Bovin IgG is in Phase 2.
Related
- Manufacturer: Johns Hopkins Bloomberg School of Public Health — full pipeline
- Also known as: Experimental
- Compare: Anti-CS17 Bovin IgG vs similar drugs
- Pricing: Anti-CS17 Bovin IgG cost, discount & access